Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
CLEO Diagnostics Ltd ( (AU:COV) ) has provided an announcement.
Cleo Diagnostics Ltd has achieved a critical milestone in the commercial production of its Ovarian Cancer diagnostic test by initiating technology transfer to a manufacturer. The company is progressing with U.S. clinical trials and is focused on submitting to the FDA to access the U.S. market by 2026. Successful clinical trials and regulatory filings in the U.S. and Australia are expected to lay the groundwork for future market expansion and applications. Cleo’s efforts align with the urgent need for early and accurate detection of Ovarian Cancer, which currently lacks a reliable diagnostic test.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is a company operating in the healthcare industry, focusing on the development of diagnostic tests for early detection of diseases. Their primary product is a blood test for the early detection of Ovarian Cancer, targeting the pre-surgical triage market. The company is committed to transforming the diagnostic sector and improving women’s health outcomes.
YTD Price Performance: 5.56%
Average Trading Volume: 167,433
Technical Sentiment Signal: Buy
See more insights into COV stock on TipRanks’ Stock Analysis page.